As of 2025-09-14, the Intrinsic Value of ImmuPharma PLC (IMM.L) is -17.14 GBP. This IMM.L valuation is based on the model Peter Lynch Fair Value. With the current market price of 14.25 GBP, the upside of ImmuPharma PLC is -220.27%.
Based on its market price of 14.25 GBP and our intrinsic valuation, ImmuPharma PLC (IMM.L) is overvalued by 220.27%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -17.14 - -17.14 | -17.14 | -220.27% |
| P/E | (21.10) - (22.58) | (21.46) | -250.6% |
| DDM - Stable | (7.36) - (24.90) | (16.13) | -213.2% |
| DDM - Multi | (6.15) - (17.35) | (9.21) | -164.6% |
| Market Cap (mil) | 24.99 |
| Beta | 0.06 |
| Outstanding shares (mil) | 1.75 |
| Enterprise Value (mil) | 24.59 |
| Market risk premium | 5.98% |
| Cost of Equity | 13.30% |
| Cost of Debt | 5.00% |
| WACC | 8.87% |